Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04384601 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer

StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 19, 2021 (before its estimated September 2022 completion). Its status may not reflect the trial's current state.

Record History

  1. Start date: Sep 2020 to Sep 2021v5
  2. Site contact updatedv4
  3. Re-verified, no change to tracked fieldsv3
  4. Eligibility criteria shortened, about 38 words Study title shortened, about 4 wordsv2 Show 1 more changeShow less
    • Study title shortened, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Ruijin Hospital
370 trials monitored
See 13 trials at risk
Gastric Cancer
1,201 trials monitored
See 59 trials at risk
DRAGON III research, Neoadjuvant Chemotherapy (FLOT versus SOX) for Gastric Cancer, is an investigator initiated; phase 3, open label, multi-center randomized controlled study.
Trial Details
NCT Number NCT04384601
Lead Sponsor Ruijin Hospital
Conditions Gastric Cancer, Neoadjuvant Chemotherapy
Enrollment 246 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov